Biotechnology
Compare Stocks
5 / 10Stock Comparison
CDT vs CSWC vs TPVG vs GAIN vs MRCC
Revenue, margins, valuation, and 5-year total return — side by side.
Asset Management
Asset Management
Asset Management
Asset Management
CDT vs CSWC vs TPVG vs GAIN vs MRCC — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Biotechnology | Asset Management | Asset Management | Asset Management | Asset Management |
| Market Cap | $368K | $1.43B | $243M | $657M | $110M |
| Revenue (TTM) | $696M | $164M | $97M | $90M | $21M |
| Net Income (TTM) | $17M | $103M | $-12M | $130M | $-5M |
| Gross Margin | 36.9% | 66.5% | 83.5% | 68.6% | 60.8% |
| Operating Margin | 6.4% | 48.5% | 77.9% | 72.7% | 51.7% |
| Forward P/E | 0.0x | 10.1x | 6.5x | 40.7x | 14.9x |
| Total Debt | $1.29B | $956M | $469M | $456M | $191M |
| Cash & Equiv. | $390M | $43M | $20M | $14M | $2M |
CDT vs CSWC vs TPVG vs GAIN vs MRCC — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Mar 22 | May 26 | Return |
|---|---|---|---|
| CDT Equity Inc. (CDT) | 100 | 0.0 | -100.0% |
| Capital Southwest C… (CSWC) | 100 | 101.1 | +1.1% |
| TriplePoint Venture… (TPVG) | 100 | 34.3 | -65.7% |
| Gladstone Investmen… (GAIN) | 100 | 102.4 | +2.4% |
| Monroe Capital Corp… (MRCC) | 100 | 42.6 | -57.4% |
Price return only. Dividends and distributions are not included.
Quick Verdict: CDT vs CSWC vs TPVG vs GAIN vs MRCC
Each card shows where this stock fits in a portfolio — not just who wins on paper.
CDT is the #2 pick in this set and the best alternative if growth is your priority.
- 8.9% revenue growth vs MRCC's -39.7%
CSWC ranks third and is worth considering specifically for momentum.
- +34.0% vs CDT's -99.8%
TPVG is the clearest fit if your priority is income & stability and growth exposure.
- Dividend streak 0 yrs, beta 0.83, yield 17.1%
- Rev growth 36.6%, EPS growth 48.8%
- NIM 7.4% vs GAIN's 5.5%
- 17.1% yield, vs CSWC's 10.2%, (1 stock pays no dividend)
GAIN carries the broadest edge in this set and is the clearest fit for long-term compounding and sleep-well-at-night.
- 319.3% 10Y total return vs CSWC's 234.2%
- Lower volatility, beta 0.53, Low D/E 91.3%, current ratio 3.69x
- Beta 0.53, yield 10.0%, current ratio 3.69x
- 72.7% margin vs CDT's 2.4%
MRCC is the clearest fit if your priority is valuation efficiency.
- PEG 0.32 vs TPVG's 6.41
- Lower P/E (14.9x vs 40.7x)
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 8.9% revenue growth vs MRCC's -39.7% | |
| Value | Lower P/E (14.9x vs 40.7x) | |
| Quality / Margins | 72.7% margin vs CDT's 2.4% | |
| Stability / Safety | Beta 0.53 vs CDT's 1.84, lower leverage | |
| Dividends | 17.1% yield, vs CSWC's 10.2%, (1 stock pays no dividend) | |
| Momentum (1Y) | +34.0% vs CDT's -99.8% | |
| Efficiency (ROA) | 10.5% ROA vs TPVG's -1.5%, ROIC 5.3% vs 7.2% |
CDT vs CSWC vs TPVG vs GAIN vs MRCC — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Segment breakdown not available.
Segment breakdown not available.
Segment breakdown not available.
CDT vs CSWC vs TPVG vs GAIN vs MRCC — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
TPVG leads in 1 of 6 categories
CDT leads 1 • CSWC leads 0 • GAIN leads 0 • MRCC leads 0 • 4 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
TPVG leads this category, winning 2 of 5 comparable metrics.
Income & Cash Flow (Last 12 Months)
CDT is the larger business by revenue, generating $696M annually — 32.8x MRCC's $21M. GAIN is the more profitable business, keeping 72.7% of every revenue dollar as net income compared to CDT's 2.4%.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $696M | $164M | $97M | $90M | $21M |
| EBITDAEarnings before interest/tax | $47M | $142M | -$22M | $58M | $11M |
| Net IncomeAfter-tax profit | $17M | $103M | -$12M | $130M | -$5M |
| Free Cash FlowCash after capex | -$6M | -$69M | $35M | -$82M | $25M |
| Gross MarginGross profit ÷ Revenue | +36.9% | +66.5% | +83.5% | +68.6% | +60.8% |
| Operating MarginEBIT ÷ Revenue | +6.4% | +48.5% | +77.9% | +72.7% | +51.7% |
| Net MarginNet income ÷ Revenue | +2.4% | +43.1% | +50.6% | +72.7% | +53.8% |
| FCF MarginFCF ÷ Revenue | -0.9% | -132.6% | -58.7% | +126.8% | +5.5% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — | — | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | +100.4% | +113.3% | -2.3% | +58.1% | -51.5% |
Valuation Metrics
CDT leads this category, winning 4 of 7 comparable metrics.
Valuation Metrics
At 0.0x trailing earnings, CDT trades at a 100% valuation discount to CSWC's 16.3x P/E. Adjusting for growth (PEG ratio), MRCC offers better value at 0.21x vs TPVG's 4.84x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $367,825 | $1.4B | $243M | $657M | $110M |
| Enterprise ValueMkt cap + debt − cash | $896M | $2.3B | $691M | $1.1B | $108M |
| Trailing P/EPrice ÷ TTM EPS | 0.00x | 16.32x | 4.91x | 9.28x | 9.58x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 10.06x | 6.50x | 40.66x | 14.94x |
| PEG RatioP/E ÷ EPS growth rate | — | — | 4.84x | — | 0.21x |
| EV / EBITDAEnterprise value multiple | 2.43x | 27.43x | 9.13x | 16.82x | — |
| Price / SalesMarket cap ÷ Revenue | 0.00x | 8.71x | 2.50x | 7.31x | 3.55x |
| Price / BookPrice ÷ Book value/share | 0.00x | 1.39x | 0.68x | 1.22x | 0.66x |
| Price / FCFMarket cap ÷ FCF | — | — | — | 5.77x | 0.95x |
Profitability & Efficiency
Evenly matched — CDT and GAIN and MRCC each lead in 3 of 9 comparable metrics.
Profitability & Efficiency
GAIN delivers a 21.9% return on equity — every $100 of shareholder capital generates $22 in annual profit, vs $-3 for TPVG. GAIN carries lower financial leverage with a 0.91x debt-to-equity ratio, signaling a more conservative balance sheet compared to TPVG's 1.33x. On the Piotroski fundamental quality scale (0–9), CDT scores 6/9 vs CSWC's 1/9, reflecting solid financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | +2.6% | +10.3% | -3.4% | +21.9% | -2.9% |
| ROA (TTM)Return on assets | +1.0% | +4.8% | -1.5% | +10.5% | -1.3% |
| ROICReturn on invested capital | +21.9% | +3.5% | +7.2% | +5.3% | +2.0% |
| ROCEReturn on capital employed | +22.2% | +4.6% | +9.4% | +6.8% | +2.6% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 1 | 5 | 4 | 6 |
| Debt / EquityFinancial leverage | 1.02x | 1.08x | 1.33x | 0.91x | 1.15x |
| Net DebtTotal debt minus cash | $896M | $913M | $449M | $441M | $189M |
| Cash & Equiv.Liquid assets | $390M | $43M | $20M | $14M | $2M |
| Total DebtShort + long-term debt | $1.3B | $956M | $469M | $456M | $191M |
| Interest CoverageEBIT ÷ Interest expense | -1.05x | 2.91x | -1.02x | 1.58x | 0.69x |
Total Returns (Dividends Reinvested)
Evenly matched — CSWC and GAIN each lead in 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in GAIN five years ago would be worth $17,205 today (with dividends reinvested), compared to $0 for CDT. Over the past 12 months, CSWC leads with a +34.0% total return vs CDT's -99.8%. The 3-year compound annual growth rate (CAGR) favors CSWC at 20.7% vs CDT's -97.4% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -94.2% | +11.4% | -6.3% | +20.7% | -11.4% |
| 1-Year ReturnPast 12 months | -99.8% | +34.0% | +19.3% | +30.8% | -6.8% |
| 3-Year ReturnCumulative with dividends | -100.0% | +75.8% | -3.4% | +56.5% | +18.0% |
| 5-Year ReturnCumulative with dividends | -100.0% | +51.4% | -13.5% | +72.0% | -0.9% |
| 10-Year ReturnCumulative with dividends | -100.0% | +234.2% | +93.3% | +319.3% | +22.8% |
| CAGR (3Y)Annualised 3-year return | -97.4% | +20.7% | -1.2% | +16.1% | +5.7% |
Risk & Volatility
Evenly matched — CSWC and GAIN each lead in 1 of 2 comparable metrics.
Risk & Volatility
GAIN is the less volatile stock with a 0.53 beta — it tends to amplify market swings less than CDT's 1.84 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CSWC currently trades 98.2% from its 52-week high vs CDT's 0.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.84x | 0.84x | 0.83x | 0.53x | 0.74x |
| 52-Week HighHighest price in past year | $1425.00 | $24.43 | $7.53 | $17.14 | $7.76 |
| 52-Week LowLowest price in past year | $1.20 | $19.37 | $4.48 | $13.11 | $4.04 |
| % of 52W HighCurrent price vs 52-week peak | +0.1% | +98.2% | +79.5% | +96.3% | +65.5% |
| RSI (14)Momentum oscillator 0–100 | 27.2 | 63.7 | 58.3 | 69.9 | 50.4 |
| Avg Volume (50D)Average daily shares traded | 126K | 664K | 504K | 371K | 156K |
Analyst Outlook
Evenly matched — CSWC and TPVG each lead in 1 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: CSWC as "Buy", TPVG as "Hold", GAIN as "Hold", MRCC as "Hold". Consensus price targets imply 57.5% upside for MRCC (target: $8) vs -9.1% for GAIN (target: $15). For income investors, TPVG offers the higher dividend yield at 17.11% vs MRCC's 0.24%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy | Hold | Hold | Hold |
| Price TargetConsensus 12-month target | — | $22.50 | $8.95 | $15.00 | $8.00 |
| # AnalystsCovering analysts | — | 10 | 12 | 7 | 11 |
| Dividend YieldAnnual dividend ÷ price | — | +10.2% | +17.1% | +10.0% | +0.2% |
| Dividend StreakConsecutive years of raises | 1 | 3 | 0 | 0 | 0 |
| Dividend / ShareAnnual DPS | — | $2.45 | $1.02 | $1.66 | $0.93 |
| Buyback YieldShare repurchases ÷ mkt cap | +28.8% | 0.0% | 0.0% | 0.0% | 0.0% |
TPVG leads in 1 of 6 categories (Income & Cash Flow). CDT leads in 1 (Valuation Metrics). 4 tied.
CDT vs CSWC vs TPVG vs GAIN vs MRCC: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is CDT or CSWC or TPVG or GAIN or MRCC a better buy right now?
For growth investors, TriplePoint Venture Growth BDC Corp.
(TPVG) is the stronger pick with 36. 6% revenue growth year-over-year, versus -39. 7% for Monroe Capital Corporation (MRCC). CDT Equity Inc. (CDT) offers the better valuation at 0. 0x trailing P/E, making it the more compelling value choice. Analysts rate Capital Southwest Corporation (CSWC) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — CDT or CSWC or TPVG or GAIN or MRCC?
On trailing P/E, CDT Equity Inc.
(CDT) is the cheapest at 0. 0x versus Capital Southwest Corporation at 16. 3x. On forward P/E, TriplePoint Venture Growth BDC Corp. is actually cheaper at 6. 5x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Monroe Capital Corporation wins at 0. 32x versus TriplePoint Venture Growth BDC Corp. 's 6. 41x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.
03Which is the better long-term investment — CDT or CSWC or TPVG or GAIN or MRCC?
Over the past 5 years, Gladstone Investment Corporation (GAIN) delivered a total return of +72.
0%, compared to -100. 0% for CDT Equity Inc. (CDT). Over 10 years, the gap is even starker: GAIN returned +319. 3% versus CDT's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — CDT or CSWC or TPVG or GAIN or MRCC?
By beta (market sensitivity over 5 years), Gladstone Investment Corporation (GAIN) is the lower-risk stock at 0.
53β versus CDT Equity Inc. 's 1. 84β — meaning CDT is approximately 244% more volatile than GAIN relative to the S&P 500. On balance sheet safety, Gladstone Investment Corporation (GAIN) carries a lower debt/equity ratio of 91% versus 133% for TriplePoint Venture Growth BDC Corp. — giving it more financial flexibility in a downturn.
05Which is growing faster — CDT or CSWC or TPVG or GAIN or MRCC?
By revenue growth (latest reported year), TriplePoint Venture Growth BDC Corp.
(TPVG) is pulling ahead at 36. 6% versus -39. 7% for Monroe Capital Corporation (MRCC). On earnings-per-share growth, the picture is similar: CDT Equity Inc. grew EPS 128. 8% year-over-year, compared to -28. 3% for Capital Southwest Corporation. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — CDT or CSWC or TPVG or GAIN or MRCC?
Gladstone Investment Corporation (GAIN) is the more profitable company, earning 72.
7% net margin versus 8. 7% for CDT Equity Inc. — meaning it keeps 72. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TPVG leads at 77. 9% versus 11. 6% for CDT. At the gross margin level — before operating expenses — TPVG leads at 83. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is CDT or CSWC or TPVG or GAIN or MRCC more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, Monroe Capital Corporation (MRCC) is the more undervalued stock at a PEG of 0. 32x versus TriplePoint Venture Growth BDC Corp. 's 6. 41x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, TriplePoint Venture Growth BDC Corp. (TPVG) trades at 6. 5x forward P/E versus 40. 7x for Gladstone Investment Corporation — 34. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for MRCC: 57. 5% to $8. 00.
08Which pays a better dividend — CDT or CSWC or TPVG or GAIN or MRCC?
In this comparison, TPVG (17.
1% yield), CSWC (10. 2% yield), GAIN (10. 0% yield), MRCC (0. 2% yield) pay a dividend. CDT does not pay a meaningful dividend and should not be held primarily for income.
09Is CDT or CSWC or TPVG or GAIN or MRCC better for a retirement portfolio?
For long-horizon retirement investors, Gladstone Investment Corporation (GAIN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
53), 10. 0% yield, +319. 3% 10Y return). CDT Equity Inc. (CDT) carries a higher beta of 1. 84 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (GAIN: +319. 3%, CDT: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between CDT and CSWC and TPVG and GAIN and MRCC?
These companies operate in different sectors (CDT (Healthcare) and CSWC (Financial Services) and TPVG (Financial Services) and GAIN (Financial Services) and MRCC (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: CDT is a small-cap deep-value stock; CSWC is a small-cap deep-value stock; TPVG is a small-cap high-growth stock; GAIN is a small-cap deep-value stock; MRCC is a small-cap deep-value stock. CSWC, TPVG, GAIN pay a dividend while CDT, MRCC do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.